Amclamed

Amclamed is an oral combination antibiotic developed and marketed by Dawa Life Sciences. It consists of amoxicillin, a beta-lactam antibiotic, and clavulanic acid, a beta-lactamase inhibitor. Amoxicillin exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs), which are essential enzymes involved in the synthesis of the bacterial cell wall. Clavulanic acid acts as a suicide inhibitor of beta-lactamase enzymes, which are produced by certain bacteria to degrade beta-lactam antibiotics. By inhibiting these enzymes, clavulanic acid protects amoxicillin from degradation and extends its spectrum of activity to include many beta-lactamase-producing organisms. Amclamed is approved for the treatment of a wide range of bacterial infections and is primarily distributed in Kenya and other sub-Saharan African markets.

Brand names

Amclamed

Other names

Amoxicillin + Clavulanic AcidAmoxicillin and Clavulanate Potassium